

1 **Progressive Increase in Virulence of Novel SARS-CoV-2 Variants in Ontario, Canada**

2

3 David N. Fisman MD MPH and Ashleigh R. Tuite PhD MPH

4

5 Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada

6

7

8 **Address reprint requests and correspondence to:**

9 David Fisman, MD MPH FRCP(C)

10 Room 686, 155 College Street, Toronto, Ontario, M5T 3M7

11 Email: [david.fisman@utoronto.ca](mailto:david.fisman@utoronto.ca)

12

13 Funding statement: The research was supported by a grant to DNF from the Canadians Institutes  
14 for Health Research (2019 COVID-19 rapid researching funding OV4-170360).

15

16 Declaration of competing interests: Dr. Fisman has served on advisory boards related to  
17 influenza and SARS-CoV-2 vaccines for Seqirus, Pfizer, Astrazeneca and Sanofi-Pasteur  
18 Vaccines, and has served as a legal expert on issues related to COVID-19 epidemiology for the  
19 Elementary Teachers Federation of Ontario and the Registered Nurses Association of Ontario.

20

21 **Abstract**

22

23 **Background:** The period from February to June 2021 was one during which initial wild-type  
24 SARS-CoV-2 strains were supplanted in Ontario, Canada, first by variants of concern (VOC)  
25 with the N501Y mutation (Alpha/B.1.1.17, Beta/B.1.351 and Gamma/P.1 variants), and then by  
26 the Delta/B.1.617 variant. The increased transmissibility of these VOCs has been documented  
27 but data for increased virulence is limited. We used Ontario's COVID-19 case data to evaluate  
28 the virulence of these VOCs compared to non-VOC SARS-CoV-2 infections, as measured by  
29 risk of hospitalization, intensive care unit (ICU) admission, and death.

30 **Methods:** We created a retrospective cohort of people in Ontario testing positive for SARS-  
31 CoV-2 and screened for VOCs, with dates of test report between February 7 and June 27, 2021  
32 (n=212,332). We constructed mixed effects logistic regression models with hospitalization, ICU  
33 admission, and death as outcome variables. Models were adjusted for age, sex, time, vaccination  
34 status, comorbidities, and pregnancy status. Health units were included as random intercepts.

35 **Results:** Compared to non-VOC SARS-CoV-2 strains, the adjusted elevation in risk associated  
36 with N501Y-positive variants was 52% (43-62%) for hospitalization; 89% (67-116%) for ICU  
37 admission; and 51% (30-74%) for death. Increases with Delta variant were more pronounced:  
38 108% (80-138%) for hospitalization; 234% (164-331%) for ICU admission; and 132% (47-  
39 230%) for death.

40 **Interpretation:** The progressive increase in transmissibility and virulence of SARS-CoV-2  
41 VOCs will result in a significantly larger, and more deadly, pandemic than would have occurred  
42 in the absence of VOC emergence.

43

44 **Introduction**

45

46 Novel SARS-CoV-2 variants of concern (VOC), including viral lineages carrying the N501Y  
47 and/or E484K mutations (Alpha/B.1.1.7, Beta/B.1.351 and Gamma /P.1, were first identified in  
48 Ontario, Canada in December 2020 (1). While infection with such lineages was initially  
49 uncommon, these VOCs outcompeted earlier SARS-CoV-2 lineages in Ontario, and as of late  
50 April 2021 comprised almost all new infections in Ontario, with Alpha being the most prevalent  
51 lineage(1). In April 2021, the B.1.617.2 variant, now known as “Delta” under revised World  
52 Health Organization nomenclature, emerged in the province and outcompeted earlier VOCs,  
53 representing the majority of infections in the province as of July 2021 (2, 3).

54

55 This serial replacement by emerging variants reflects progressively higher effective reproduction  
56 numbers which allow novel variants to outcompete previously dominant strains in the face of  
57 identical disease control interventions (4-6). However, VOCs are also concerning because of an  
58 apparent increase in virulence, with increased risk of hospitalization, intensive care unit  
59 admission and death, after adjustment for age and other predictive factors (7-10). Although the  
60 increased virulence of strains with the N501Y mutation relative to strains which lack this  
61 mutation has been described (7-9), only limited information is available on the virulence of  
62 infection with the Delta variant, relative to earlier N501Y-positive VOCs (i.e., Alpha, Beta, and  
63 Gamma) (10). Our objectives were (i) to use Ontario’s COVID-19 case data to evaluate the  
64 virulence of N501Y-positive variants relative to earlier SARS-CoV-2 lineages; and (ii) to  
65 evaluate the virulence of the Delta variant of SARS-CoV-2 relative to N501Y-positive VOCs.

66

67

## 68 **Methods**

69

### 70 *Data Sources*

71 We created a retrospective cohort of people in Ontario testing positive for SARS-CoV-2 and  
72 screened for variants of concern, with dates of test report between February 7 and June 22, 2021.  
73 Case information was extracted from the Ontario provincial Case and Contact Management  
74 (CCM) database as described elsewhere (11). Although VOC cases were identified in Ontario  
75 beginning in December 2020, systematic screening was not implemented until February 2021,  
76 after which time all COVID-19 PCR positive specimens with a cycle threshold (Ct) value  $\leq 35$   
77 were screened for the N501Y mutation using a single nucleotide polymorphism real-time PCR  
78 assay developed at the Public Health Ontario Laboratory. On March 22, 2021, Ontario initiated  
79 universal screening for N501Y and E484K mutations using a multiplex real-time PCR assay on  
80 all specimens testing positive for SARS-CoV-2 with a Ct value  $\leq 35$ . Whole genome sequencing  
81 (WGS) was performed on a 5% sample of specimens regardless of the presence of mutations.  
82 Initially all specimens with the N501Y and/or E484K mutation and Ct value  $\leq 30$  were  
83 sequenced; however, as of June 2021 routine WGS was no longer performed on specimens  
84 without E484K, under the presumption that such specimens were of the Alpha lineage. By late  
85 April 2021, more than 90% of infections in Ontario were screen positive for N501Y(Figure 1);  
86 subsequently, N501Y mutations became less common, and N501Y-negative specimens subjected  
87 to WGS were demonstrated to be predominantly Delta variant, with Delta representing  $> 60\%$  of  
88 new infections in Ontario on July 1, 2021 (2, 3). Analyses were restricted to individuals whose  
89 viral isolate had been screened for a VOC. Cases were classified as N501Y-positive (screening  
90 positive for N501Y or identified as Alpha, Beta, or Gamma by WGS), probable Delta variant  
91 (identified by WGS at any point in time or negative for N501Y and any other mutations from

92 May 1, 2021 onward), or not VOC (all N501Y negative cases between February 7 and April  
93 30, 2021 and all non-Delta cases testing positive for a mutation other than N501Y regardless of  
94 date). Individuals for whom VOC screening information was not available (N = 31,464), or for  
95 whom screening could not be completed (N = 13,579) were excluded from the analysis. We  
96 further restricted our analysis to individuals without a record of long-term care residence, as the  
97 epidemiology and severity of SARS-CoV-2 infection in long-term care home residents have been  
98 distinct in Ontario (12, 13). The dataset was extracted on July 13, 2021, with the most recent test  
99 report date of July 12, 2021. We included cases with a test report date at least 14 days prior (June  
100 27, 2021) to account for delays between testing and occurrence of hospitalization, intensive care  
101 unit (ICU) admission, and death. Vaccination data for cases, including dates of administration of  
102 first and second doses of approved SARS-CoV-2 vaccines (where relevant) were obtained from  
103 COVaxON, a centralized COVID-19 vaccine information system for the province. Individuals  
104 were categorized as fully vaccinated if the case episode date occurred 7 or more days after  
105 receipt of the second dose; partially vaccinated if the case episode date occurred 14 days or more  
106 after receipt of the first dose but less than 7 days after receipt of the second dose; and  
107 unvaccinated otherwise.

#### 108 *Analysis*

109 We constructed mixed effects logistic regression models with hospitalization, ICU admission,  
110 and death as dependent variables. Models were adjusted for age (by 10-year increments), male  
111 sex, time (modeled as a week-on-week linear trend), vaccination status, and any documented  
112 major comorbidity (including asthma, COPD, hematological disease, liver disease, cardiac  
113 disease, diabetes, immune compromise, renal disease, neurological disease, malignancy, or  
114 obesity). Hospitalization and ICU models were also adjusted for pregnancy, which was excluded

115 from models evaluating death due to the rarity of fatalities among pregnant individuals. Due to  
116 geographic variation in prevalence of variants, health units were included as random intercepts.  
117 Confidence intervals were calculated by parametric bootstrap, assuming fixed effects. As  
118 hospitalization, ICU admission and death were fortunately relative rare among cases, we  
119 considered odds ratios to approximate relative risks under the “rare disease assumption” (14). In  
120 a separate analysis, we explored the apparent linear increase in virulence from non-VOC to  
121 N501Y-positive VOC to Delta variant by modeling VOC status of cases as a 3-level ordinal  
122 variable. We conducted all analyses in R version 4.1.0 using the lme4 and broom.mixed  
123 packages (15-17). The study was conducted in accordance with the STROBE guidelines for  
124 observational research (18), and received ethics approval from the Research Ethics Board at the  
125 University of Toronto.

126

## 127 **Results**

128

129 We included 212,332 cases in our analysis, with test report dates between February 7 and June  
130 27, 2021. Changes over time in incidence of infections by VOC status, and in incidence of  
131 infections resulting in ICU admission, are presented in **Figure 1**. Among all reported cases, 77%  
132 were infections with N501Y-positive VOC; 2.7% were classified as probable Delta infections.  
133 In crude comparisons, there were significant differences between variants in probability of  
134 hospitalization and ICU; individuals with N501Y-positive variants and probable Delta infection  
135 were significantly younger and less likely to have comorbidities than individuals with non-VOC  
136 infections; N501Y-positive infections were significantly more common in the Greater Toronto  
137 and Hamilton area (GTHA, the province’s largest metropolitan area); Delta variant infections

138 were significantly less common in Ottawa (the province's second largest metropolitan area)  
139 (**Table 1**).

140

141 After adjustment for age, sex, vaccination status, comorbidities, health unit, and temporal trend,  
142 large and significant increases in the risk of hospitalization, ICU admission, and death were seen  
143 with both N501Y-positive VOC, and probable Delta infections, relative to non-VOC (**Table 2**).

144 Adjusted risks of hospitalization, ICU admission and death were 52% (43-62%), 89% (67-116%)  
145 and 51% (30-74%) higher with N501Y-positive VOC than with non-VOC; respective differences  
146 between non-VOC and Delta infections were 108% (80-138%), 234% (164-331%), and 132%  
147 (47-230%). We identified a linear increase in severity with progression from non-VOC

148 infections to N501Y-positive infections, to Delta variant infections, with relative increases in risk  
149 of hospitalization, ICU admission and death of 49% (41-58%), 86% (68-109%) and 51% (32-  
150 72%), respectively (**Table 3**).

151

152 **Discussion**

153 The emergence of novel SARS-CoV-2 variants of concern has slowed progress against the  
154 pandemic in three distinct ways: (i) by increasing transmissibility and the disease's reproduction  
155 number; (ii) by increasing immune escape and diminishing vaccine effectiveness; and (iii) by  
156 increasing the virulence of SARS-CoV-2 infection. Credible reports of enhanced virulence of  
157 VOC with the N501Y mutation have emerged over the past several months (7-9), but to our  
158 knowledge this is one of the first analyses to demonstrate enhanced virulence of the Delta variant  
159 (10).

160

161 We show that in the Canadian province of Ontario, VOCs with the N501Y mutation were  
162 associated with a markedly increased risk of hospitalization, intensive care unit admission and  
163 death among infected individuals, but that the Delta variant, which is now supplanting these  
164 other VOCs in Ontario, has increased these risks even further. Individuals infected with VOCs  
165 were, on average, younger and less likely to have comorbid conditions than those infected with  
166 non-VOC, but nonetheless had higher crude risks of hospitalization and ICU admission. Once  
167 we adjusted for confounding factors such as age, vaccination status, comorbidity, and temporal  
168 trends, elevated per-infection risk, including risk of death, remained markedly higher with  
169 VOCs, and with Delta in particular. Indeed, given the relatively small number of Delta  
170 infections in our time series, it is remarkable that a clear and significant elevation of risk of even  
171 uncommon, delayed outcomes, such as death, is readily visible in our analysis.

172

173 Canada is now one of the most widely vaccinated countries in the world with respect to SARS-  
174 CoV-2, and vaccination has undoubtedly blunted the impact of emergence of these VOCs. We



175 find a marked reduction in risk of severe disease and death among both partially and fully  
176 vaccinated individuals in our study, consistent with the findings of Nasreen and colleagues (19).  
177 Notably, our analysis is performed in a case-only dataset, so the effects we report here  
178 (approximately 80-90% protection against death), represent a substantial degree of protection  
179 conferred by vaccines even when they fail to prevent infection. Such direct protective effects  
180 may help reduce the health impacts of ongoing SARS-CoV-2 transmission in Ontario, even if  
181 herd immunity proves elusive due to the high reproduction numbers of VOC (5, 6).

182  
183 Even after adjustment for vaccination status we observed downward temporal trends in case  
184 severity, with a week-on-week reduced risk of hospitalization, ICU admission and death of  
185 approximately 0.5% (0-1.2%), 1.9% (0.8-3.1%) and 3.9% (2.5% to 5.4%), respectively. We  
186 suspect this decrease may represent attenuation of illness by vaccination in individuals who  
187 would not have been considered partly or fully vaccinated using our definitions, due to  
188 inadequate time elapsed since vaccination. This decrease may also represent residual  
189 confounding by changing age distribution of cases over time, perhaps not captured by our broad  
190 10-year age categories, due to early prioritization of older individuals for vaccination in the  
191 province of Ontario (20).

192  
193 An important limitation in our analysis is the possibility of our having misclassified early Delta  
194 variant infections as non-VOC due to the absence of routine screening for characteristic Delta  
195 mutations, with likely underestimation of the prevalence of Delta prior to May 2021. We caution  
196 that such misclassification may have biased our estimates of severity downwards, and our  
197 estimates of excess risk for Delta are likely biased towards the null.

198

199 In summary, we demonstrate that in the Canadian province of Ontario, despite widespread  
200 vaccination and VOC infections occurring more frequently in younger and healthier individuals,  
201 VOCs are associated with a substantial increase in virulence, including increased risk of death.  
202 The Delta variant is more virulent than previously dominant N501Y-positive VOCs. Combined  
203 with increased transmissibility and immune escape, these VOCs represent a significant escalation  
204 in risk to public health during the SARS-CoV-2 pandemic.

205

## 206 **Acknowledgements**

207 The authors wish to thank the staff at Public Health Ontario and Ontario's public health units for  
208 collecting, sequencing, analyzing, and providing access to the data used for this analysis.

**Table 1. Characteristics of study cohort by variant of concern (VOC) status.**

<b>Descriptor</b>	<b>All</b>	<b>VOC Not Detected</b>	<b>N501Y+ VOC</b>	<b>Probable Delta VOC</b>	<b>P-value</b>
<b>Total Cases</b>	212,332	43,420	162,923	5,989	
<b>Hospitalized (%)</b>	11,041 (5.2)	1,916 (4.4)	8,776 (5.4)	349(5.8)	<0.001
<b>Admitted to ICU</b>	2,325 (1.1)	338 (0.8)	1,897 (1.2)	90 (1.5)	< 0.001
<b>Died</b>	1821 (0.9)	385 (0.9)	1,396 (0.9)	40 (0.7)	0.23
<b>Male (%)</b>	107,583 (50.7)	22,023 (50.7)	82,506 (50.6)	3,054 (51.0)	0.84
<b>Under 60 years</b>	182,030 (85.7)	36,441 (83.9)	140,338 (86.1)	5251 (87.7)	< 0.001
<b>Vaccination status</b>					
<b>Partially vaccinated</b>	72,841 (34.3)	16,930 (39.0)	54,211(33.3)	1,700 (28.4)	< 0.001
<b>Fully vaccinated</b>	945 (0.4)	142 (0.3)	732 (0.4)	71 (1.2)	< 0.001
<b>Comorbidity*</b>	10,805 (5.1)	2,940 (6.8)	7,547 (4.6)	318 (5.3)	< 0.001
<b>Pregnancy</b>	555 (0.3)	124 (0.3)	410 (0.2)	21 (0.4)	0.18
<b>Geography</b>					
<b>GTHA†</b>	156,809 (73.9)	27,537 (63.4)	125,383 (77.0)	3,889 (64.9)	<0.001
<b>Ottawa</b>	9,326 (4.4)	1,875 (4.3)	7,334 (4.5)	117 (2.0)	<0.001

**NOTE:** P-values based on chi-squared test.

\*Comorbidities include one or more of asthma, COPD, hematological disease, liver disease, cardiac disease, diabetes, immune compromise, renal disease, neurological disease, malignancy, or obesity.

†GTHA, Greater Toronto Area and Hamilton, large conurbation in Central Ontario consisting of 6 health units (Toronto, Peel, Durham, Halton, York and Hamilton).

**Table 2. Adjusted odds ratios for hospitalization, ICU admission, and death among reported COVID-19 cases.**

<b>Covariate</b>	<b>Hospitalization</b>		<b>ICU Admission</b>		<b>Death</b>	
	<b>OR</b>	<b>95% CI</b>	<b>OR</b>	<b>95% CI</b>	<b>OR</b>	<b>95% CI</b>
<b>VOC status</b>						
<b>Probable Delta variant</b>	2.08	(1.80 to 2.38)	3.34	(2.64 to 4.31)	2.32	(1.47 to 3.30)
<b>N501Y+ variant</b>	1.52	(1.43 to 1.62)	1.89	(1.67 to 2.16)	1.51	(1.30 to 1.74)
<b>Male sex</b>	1.29	(1.24 to 1.35)	1.60	(1.46 to 1.73)	1.66	(1.48 to 1.84)
<b>Age (per 10-year increase)</b>	2.07	(2.05 to 2.10)	1.96	(1.91 to 2.00)	3.46	(3.31 to 3.58)
<b>Vaccination status</b>						
<b>Partially vaccinated</b>	0.42	(0.40 to 0.44)	0.28	(0.25 to 0.31)	0.09	(0.08 to 0.10)
<b>Fully vaccinated</b>	0.31	(0.26 to 0.43)	0.15	(0.05 to 0.28)	0.21	(0.09 to 0.32)
<b>Comorbidity</b>	2.76	(2.59 to 2.93)	2.58	(2.30 to 2.88)	2.40	(2.09 to 2.76)
<b>Pregnancy</b>	6.26	(4.48 to 8.42)	6.85	(3.51 to 1100)	---	---
<b>Series week</b>	0.994	(0.988 to 1.00)	0.981	(0.969 to 0.992)	0.961	(0.946 to 0.975)


**Table 3. Relative increase in odds ratio for hospitalization, ICU admission and death with Delta VOC as compared to N501Y-positive VOC.**

<b>Outcome</b>	<b>Effect of Delta vs. N501Y+ VOC</b>		
	<b>OR</b>	<b>LCL</b>	<b>UCL</b>
<b>Hospitalization</b>	1.49	1.41	1.58
<b>ICU Admission</b>	1.86	1.68	2.09
<b>Death</b>	1.51	1.32	1.73

Additional model covariates included: sex, age, vaccination status, comorbidity, pregnancy, series week, and health unit.

**Figure 1. Trends in SARS-CoV-2 Case Occurrence and distribution of hospitalizations, ICU admission, and deaths by VOC status in Ontario, Canada.**

(A) Cases of reported SARS-CoV-2 infection by test report date, presented as 7-day average for cases reported between February 7 and June 27, 2021. (B) Distribution of COVID-19 hospitalized cases, cases admitted to ICU, and deaths by VOC status, by week of test report. Cases are coloured by assigned VOC status. Prior to May 1, 2021, Delta cases were only detected by whole genome sequencing. After May 1, 2021, all screened specimens not identified as an N501Y-positive VOC or another variant were classified as probable Delta VOC infections.



## References

1. Tuite AR, Fisman DN, Oduyayo A, Bobos P, Allen V, Bogoch I, et al. COVID-19 hospitalizations, ICU admissions and deaths associated with the new variants of concern. Accessed 5 Jul 2021: <https://doi.org/10.47326/ocsat.2021.02.18.1.0>. 2021.
2. Public Health Ontario. Epidemiologic summary: SARS-CoV-2 whole genome sequencing in Ontario, June 30, 2021. Accessed 5 Jul 2021: [https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc\\_lang=en](https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-sars-cov2-whole-genome-sequencing-epi-summary.pdf?sc_lang=en). 2021.
3. Public Health Ontario. Epidemiologic summary: Estimating the prevalence and growth of SARS-CoV-2 variants in Ontario using mutation profiles. Accessed 5 Jul 2021: [https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc\\_lang=en](https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-prevalence-growth-voc-mutation-epi-summary.pdf?sc_lang=en). 2021.
4. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*. 2021;372(6538).
5. Brown KA, Joh E, Buchan SA, Daneman N, Mishra S, Patel S, et al. Inflection in prevalence of SARS-CoV-2 infections missing the N501Y mutation as a marker of rapid Delta (B.1.617.2) lineage expansion in Ontario, Canada. medRxiv. 2021:2021.06.22.21259349.
6. Brown KA, Gubbay J, Hopkins J, Patel S, Buchan SA, Daneman N, et al. Rapid Rise of S-Gene Target Failure and the UK variant B.1.1.7 among COVID-19 isolates in the Greater Toronto Area, Canada. medRxiv. 2021:2021.02.09.21251225.



7. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. *BMJ*. 2021;373:n1412.
8. Bager P, Wohlfahrt J, Fonager J, Rasmussen M, Albertsen M, Michaelsen TY, et al. Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study. *Lancet Infect Dis*. 2021.
9. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. *Euro Surveill*. 2021;26(16).
10. Sheikh A, McMenamin J, Taylor B, Robertson C, Public Health S, the EIIC. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet*. 2021;397(10293):2461-2.
11. Fisman DN, Greer AL, Hillmer M, O'Brien SF, Drews SJ, Tuite AR. COVID-19 case age distribution: correction for differential testing by age. *medRxiv*. 2020:2020.09.15.20193862.
12. Stall NM, Jones A, Brown KA, Rochon PA, Costa AP. For-profit long-term care homes and the risk of COVID-19 outbreaks and resident deaths. *CMAJ*. 2020;192(33):E946-E55.
13. Fisman DN, Bogoch I, Lapointe-Shaw L, McCready J, Tuite AR. Risk factors associated with mortality among residents with coronavirus disease 2019 (COVID-19) in long-term care facilities in Ontario, Canada. *JAMA Netw Open*. 2020;3(7):e2015957.
14. Greenland S, Thomas DC. On the need for the rare disease assumption in case-control studies. *Am J Epidemiol*. 1982;116(3):547-53.
15. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. 2021.

16. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. *J Stat Softw.* 2015;67(1):1-48.
17. Bolker B, Robinson D. broom.mixed: Tidying methods for mixed models. R package version 0.2.7. <https://CRAN.R-project.org/package=broom.mixed>. 2021.
18. von Elm E, Altman DG, Egger M, Pocock SJ, Gotsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Bull World Health Organ.* 2007;85(11):867-72.
19. Nasreen S, He S, Chung H, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. *medRxiv.* 2021:2021.06.28.21259420.
20. Government of Ontario. Ontario's COVID-19 vaccination plan. Available via the Internet at <https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan>. Last accessed July 13, 2021. 2021.